Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-3 of 3 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-3 of 3 studies
-
Restore CFTR ProteinClosed to Enrollment
SNO7: Phase 2 study of N91115 in adults with CF who are currently taking ivacaftor , protocol number Nivalis N91115-2CF-06This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the oral drug N91115 and will use a placebo control.
-
Age:
18 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
12 weeks
-
-
Restore CFTR ProteinCompleted with Results
SNO6: Phase 2 study of N91115 in adults with CF who are currently taking lumacaftor/ivacaftor , protocol number Nivalis N91115-2CF1-05This study evaluated the safety and effectiveness of the CFTR modulator drug N91115 (cavosonstat). This study was for adults with cystic fibrosis who have two copies of the F508del CFTR mutation and were also taking lumacaftor/ivacaftor (Orkambi®).
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 85%
-
Number of Visits:
10
-
Length of Participation:
16 weeks
-
-
Restore CFTR ProteinCompleted with Results
SNO4: Study of N91115 in people with cystic fibrosis ages 18 and older with two copies of F508del-CFTR mutation , protocol number Nivalis N91115-2CF-03This study looked at the safety and tolerability of the drug, N91115, in people with CF that had two copies of the F508del mutation. Researchers also looked at the effect of N91115 on CFTR biomarkers, such as sweat chloride value. Biomarkers help researchers understand how active or inactive a disease is.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
8
-
Length of Participation:
6 weeks
-
Showing 1-3 of 3 studies
- 1
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More